Stan Berenshteyn
Stock Analyst at Wells Fargo
(1.08)
# 3,789
Out of 5,174 analysts
85
Total ratings
34%
Success rate
-16.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTEV Claritev | Maintains: Equal-Weight | $30 → $22 | $15.35 | +43.32% | 3 | Mar 19, 2026 | |
| HCAT Health Catalyst | Downgrades: Equal-Weight | $5 → $1 | $1.10 | -8.68% | 8 | Mar 18, 2026 | |
| VEEV Veeva Systems | Maintains: Overweight | $333 → $317 | $179.11 | +76.99% | 10 | Mar 5, 2026 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $7 → $3.5 | $2.04 | +71.57% | 9 | Mar 4, 2026 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $8 → $6 | $5.42 | +10.70% | 4 | Feb 26, 2026 | |
| WAY Waystar Holding | Maintains: Overweight | $41 → $36 | $24.03 | +49.81% | 2 | Feb 19, 2026 | |
| DOCS Doximity | Maintains: Overweight | $55 → $45 | $24.34 | +84.88% | 14 | Feb 6, 2026 | |
| PHR Phreesia | Initiates: Overweight | $30 | $11.28 | +165.96% | 1 | Jan 9, 2026 | |
| HNGE Hinge Health | Initiates: Overweight | $68 | $40.91 | +66.22% | 1 | Jan 9, 2026 | |
| OMDA Omada Health | Initiates: Equal-Weight | $17 | $13.40 | +26.87% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $52 | $34.46 | +50.90% | 18 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $5.76 | +56.25% | 5 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $125 | $82.10 | +52.25% | 9 | Feb 26, 2025 |
Claritev
Mar 19, 2026
Maintains: Equal-Weight
Price Target: $30 → $22
Current: $15.35
Upside: +43.32%
Health Catalyst
Mar 18, 2026
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $1.10
Upside: -8.68%
Veeva Systems
Mar 5, 2026
Maintains: Overweight
Price Target: $333 → $317
Current: $179.11
Upside: +76.99%
GoodRx Holdings
Mar 4, 2026
Maintains: Overweight
Price Target: $7 → $3.5
Current: $2.04
Upside: +71.57%
Teladoc Health
Feb 26, 2026
Maintains: Equal-Weight
Price Target: $8 → $6
Current: $5.42
Upside: +10.70%
Waystar Holding
Feb 19, 2026
Maintains: Overweight
Price Target: $41 → $36
Current: $24.03
Upside: +49.81%
Doximity
Feb 6, 2026
Maintains: Overweight
Price Target: $55 → $45
Current: $24.34
Upside: +84.88%
Phreesia
Jan 9, 2026
Initiates: Overweight
Price Target: $30
Current: $11.28
Upside: +165.96%
Hinge Health
Jan 9, 2026
Initiates: Overweight
Price Target: $68
Current: $40.91
Upside: +66.22%
Omada Health
Jan 9, 2026
Initiates: Equal-Weight
Price Target: $17
Current: $13.40
Upside: +26.87%
Jan 5, 2026
Maintains: Overweight
Price Target: $43 → $52
Current: $34.46
Upside: +50.90%
Nov 5, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $5.76
Upside: +56.25%
Feb 26, 2025
Maintains: Overweight
Price Target: $110 → $125
Current: $82.10
Upside: +52.25%